الفهرس 
Review of literatureOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
Cancer is one of the leading diseases that cause millions of deaths
worldwide. The overall survival rate of patients remains low, despite
significant improvements in life expectancy achieved by innovations in
cancer therapy and diagnosis. Therefore, the search for new, effective,
and low-toxic anticancer agents is one of the most important tasks of
modern medicinal chemistry. In general, the solution of this problem
comes down to finding new compounds that would act on molecular
targets that play an important role in carcinogenesis. Numerous studies in
this field have shown that topoisomerases I and II are molecular targets in
the development of modern anticancer agents for an increasing number of
anticancer drugs. A large number of organic compounds belonging to
different classes are known to be capable of inhibiting topoisomerases,
including those isolated from the natural sources; for example,
camptothecin (CPT), podophyllotoxin, anthracyclines, polyene acids, and
many others. However, along with their efficacy, some of these
compounds have several substantial disadvantages. High toxicity towards
the healthy cells, low bioavailability, and cancer cells resistance are the
main drawbacks. The ways to overcome these shortcomings include the
preparation of anticancer drugs with high potency and selectivity with
improved pharmacological properties. Therefore, numerous researchers
have been carrying out an intensive effort to develop anticancer agents
either natural or synthetic that target the topoisomerase enzymes with aim
to control and treat the disease via altering the catalytic activity of Topo I
or Topo II